IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
May 18, 2022
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) — via InvestorWire — IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Capitalizing on Psychedelics Drug Market, with 13 Wellness Clinics Across Nine States and Growing
May 17, 2022
Delic Holdings Corp. comprises several businesses—Delic Labs, Meet Delic, and Ketamine Wellness Centers and media properties Reality Sandwich and Delic Radio The psychedelic drugs market is expected to reach US $9,818.68 million by 2029 – primarily driven by an increase in acceptance for use in mental health The company’s goal is to expand its clinic […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Issues Update on Default Status
May 16, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that it is providing a default status report; the report is being released in accordance with the alternative information guidelines set out in National Policy 12-203 — Management Cease Trade Orders (“NP 12-203”). According to the […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Enters New VA Partnership in Arizona
May 12, 2022
Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today announced a new partnership with the Veterans Administration (“VA”) in Arizona. Per the update, veterans suffering from treatment-resistant depression, PTSD and anxiety will have access to ketamine therapy at KWC […]
Silo Pharma Inc. (SILO) Spotlight: Ketamine
May 11, 2022
Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO), Frontage Laboratories to Collaborate in Pharmacokinetic Study
May 6, 2022
Silo Pharma (OTCQB: SILO) recently announced an agreement with Frontage Laboratories, a contract research organization, for an Investigational New Drug (“IND”)-enabling pharmacokinetic study. “Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” a recent article reads. “Frontage will study Silo’s central nervous system peptide, […]
Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial
May 6, 2022
Cybin has selected Clinilabs Drug Development Corporation as CRO for its Phase 1/2a clinical trial evaluating CYB003 for treating major depressive disorder (“MDD”) MDD impacts more than 264 million people worldwide, is a leading cause of mental disability worldwide Preclinical studies show CYB003 may have significant advantages over classic psilocybin In a significant step forward […]
InvestorNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article
May 5, 2022
Pasithea Therapeutics’ (NASDAQ: KTTA) CEO, Dr. Tiago Reis Marques, a psychiatrist at one of the top psychiatry centers in the world, a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London, was featured in a recent Forbes article. The piece, titled “You May Soon Find Mental Health Help […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO Featured on Success Story Podcast
May 5, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its cofounder and CEO Matt Stang were spotlighted in a recent episode of The Success Story podcast. During the interview, Stang talked all things Delic, including a history of the company, his decision to pivot […]
InvestorNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Preclinical Study Findings to Be Showcased at Global Event Focused on Psychedelic-Assisted Therapy
May 5, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an abstract highlighting preclinical data for its deuterated psilocybin analog CYB003 has been selected for a poster presentation at the “From Research to Reality” Global Summit on Psychedelic-Assisted Therapies and Medicines. The event is slated to take […]
IBN (InvestorBrandNetwork) Announces Success Story Podcast Interview with Delic Holdings Corp Co-Founder and CEO Matt Stang
May 5, 2022
LOS ANGELES, May 05, 2022 (GLOBE NEWSWIRE) — via InvestorWire – IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Matt Stang, Co-founder and CEO of Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, recently appeared on The Success Story Podcast, […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Ketamine Wellness Centers Now Offer NAD+ Infusion Therapy
May 4, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its Ketamine Wellness Centers (“KWC”) are now offering NAD+ infusion therapy at six clinic locations. KWC is the largest ketamine therapy provider in the country to offer the therapy, which is administered intravenously or intramuscularly. […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Set to Present Update on its Psychedelic Wellness Ecosystem at Las Vegas MicroCap Event
May 3, 2022
Delic Holdings Corp was founded four years ago, devoted to making psychedelic drug therapies available to patients with hard-to-treat mental and emotional conditions The company’s research arm has received authorization in Canada to work with substances such as psilocybin, MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B In the United States, the company operates the […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Driving the Psychedelic Conversation Forward Through Education, Research, and Service Delivery
April 29, 2022
Delic is committed to bringing science-backed benefits to as many people as possible while also changing the narrative around psychedelics It seeks to achieve this through education, products and services, and research on psychedelics So far, LSD and psilocybin have proven to reduce end of life (“EOL”) anxiety for terminally ill patients Delic recognizes the […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Doses First Patient in Clinical Trial for Psilocybin-Assisted Therapy Targeting BED
April 28, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the first patient has been dosed in the company’s phase II clinical trial for its lead candidate, TRP-8802. In combination with psychotherapy, TRP-8802 is intended as a potential treatment of binge […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Participate in Upcoming Planet MicroCap Showcase
April 28, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, will be presenting at this year’s Planet MicroCap Showcase; the event is scheduled for May 3–5, 2022. During the showcase, Delic Holdings cofounder and CEO Matt Stang will be sharing an overview of the company, including […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Focusing on Largely Underserved Indications
April 27, 2022
Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has long been familiar with the potential of psychedelics. A recent article, which contains excerpts from a New York Times writeup entitled “The Psychedelic Revolution Is Coming,” documents the increased urgency to develop new therapeutics. “This urgency aligns […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) KWC Committed to Providing Clinically-Backed, Accessible, Affordable Treatments
April 27, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, through its subsidiary and the largest ketamine therapy provider in the United States, Ketamine Wellness Centers (“KWC”), recently announced the expansion of its treatment options to include SPRAVATO(R) nasal spray for adults. The first FDA-approved ekestamine nasal spray for adults, SPRAVATO is made explicitly […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Moves to Become the Go-To Provider of Psychedelic Medicine Treatment as it Seeks Approval of Additional Compounds
April 27, 2022
Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment options The company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 disease Delic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Continues Investor Outreach as Psychedelic Wellness Drug Development Advances
April 25, 2022
Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment
April 21, 2022
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has partnered with Clinilabs Drug Development Corporation to work on its upcoming phase 1/2a clinical trial of CYB003. Clinilabs is a global, full-service contract research organization that has built a reputation for its expertise in central nervous system drug development. Derived […]
Silo Pharma Inc. (SILO) Advances with Pharmacokinetic Study – but What is Pharmacokinetics?
April 21, 2022
On March 31, 2022, Silo Pharma (OTCQB: SILO) announced an agreement with contract research organization Frontage Laboratories for an Investigational New Drug (“IND”)-enabling, “Pharmacokinetic Study.” Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Frontage will study Silo’s Central Nervous System Peptide, SPU-16, “a […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Produces First Batch of SPU-21 Liposomes for RA Study
April 20, 2022
Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. The company today announced that it has produced its first batch of liposomes for use in a preclinical study that will be conducted by Frontage Laboratories, a CRO (contract research organization). According to the update, the ability […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Achieves Key Milestone in the Advancement of Its Research Efforts
April 20, 2022
Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic research The company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposes With this significant milestone, Delic Labs is leading […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Participate at Sequire Cannabis and Psychedelic Conference, Scottsdale Capital Event
April 19, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its co-founder and CEO Matt Stang will participate at the Sequire Cannabis and Psychedelic Conference and the Scottsdale Capital Event. Stang will present the company’s performance and industry outlook and participate in one-on-one […]
NobleCon18 Investor Conference Returns as Live Event in Miami
April 18, 2022
Emerging-market company event also to be available to the public at channelchek.com MIAMI, April 18, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Noble Capital Markets (“Noble”) is pleased to announce that NobleCon18 Small & Microcap Investor Conference is kicking off this week as an in-person event at Miami’s Hard Rock Guitar Hotel, featuring 100 presenting […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Continues Expansion to Make Science-Backed Psychedelic Medicines Accessible to Patients with Mental Health Conditions
April 18, 2022
Delic opened two new KWC clinics in Q1 2022, bringing the total number of locations to 13, with plans to open more within the next 18 months The company also saw the introduction of SPRAVATO(R) nasal spray as a treatment option for treatment-resistant depression It is also expanding its ability to research novel compounds and […]
Home Bistro Inc. (HBIS) Is ‘One to Watch’
April 18, 2022
Home Bistro’s strategic acquisition of California-based Model Meals meal delivery brand created bicoastal operations The company over the past 12 months has added five celebrity chefs to the Home Bistro platform Home Bistro recently relocated its East Coast operations to a state-of-the-art South Florida food production and fulfillment facility, creating a highly cost-effective infrastructure The […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Health Canada 56 Exemption for Research on Psychedelic Compounds
April 13, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, and its subsidiary Delic Labs have received a Health Canada 56 Research Exemption. The exemption gives approval for the company to conduct research and perform tests on several compounds, including MDMA, LSD, mescaline and 2C-B. The […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Introduces FDA-Approved SPRAVATO(R) Nasal Spray at KWC Clinics in a Move to Make Mental health Treatment Effective and Affordable
April 13, 2022
Ketamine Wellness Centers (“KWC”), a subsidiary of Delic Holdings, just expanded its treatment options to include SPRAVATO(R) nasal spray beginning April 1 SPRAVATO received FDA approval back in 2019 and would be used in conjunction with an oral antidepressant Its introduction to KWC clinics underscores the company’s commitment to providing clinically-backed, accessible and affordable treatments […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements
April 12, 2022
In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in […]
Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’
April 11, 2022
Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine” Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution […]
InvestorNewsBreaks – Why Silo Pharma Inc. (SILO) Is ‘One to Watch’
April 7, 2022
Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Boundaries in Research of New Products
April 6, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products, such as psychedelics and cannabis, for the market. The company understands that research is integral for the rapidly developing psychedelics and cannabis industries, and for […]
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO to Present at Three Upcoming Investor Conferences Spotlighting the Company’s Strategic Outlook for the Remainder of 2022
April 4, 2022
Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences Conference In presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the year During a […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Enters Agreement to Significantly Advance Technologies ‘Closer to the Clinic’
March 31, 2022
Silo Pharma (OTCQB: SILO) is a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. Silo Pharma today announced its entry into an agreement with Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to […]
InvestorNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces New Clinic Openings as Company’s Expansion Accelerates
March 31, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is opening Ketamine Wellness Centers (“KWC”) in Salt Lake City and Reno, Nevada, with additional locations planned to open this year. The company also announced that it is adding SPRAVATO(R), the first FDA-approved nasal spray, as a treatment option […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Treatment Options to Add FDA-Approved Esketamine Nasal Spray
March 30, 2022
Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its treatment options to include SPRAVATO(R) nasal spray. KWC clinics located in Houston, Las Vegas and Seattle will begin offering this treatment option on April 1. According to the announcement, SPRAVATO is […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Initiates Coverage with InvestorBrandNetwork
March 30, 2022
Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has partnered with InvestorBrandNetwork (“IBN”) for its corporate communications. IBN is a multifaceted financial news and publishing company focused on private and public entities. Silo works to develop innovative solutions that address serious conditions such as post-traumatic stress […]
Silo Pharma Inc. (SILO) Is ‘One to Watch’
March 30, 2022
Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system The […]